Lycium barbarum inhibits growth of estrogen receptor positive human breast cancer cells by favorably altering estradiol metabolism

Nutrition and Cancer

Volumn 61, Issue 3, 2009, Pages 408-414

  Li, Go ^a   Sepkovic, Daniel W ^b   Bradlow, H Leon ^b   Telang, Nitin T ^a   Wong, George Y C ^a  

^a STRANG CANCER PREVENTION CENTER   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; ESTRADIOL; ESTRIOL; ESTROGEN RECEPTOR; LYCIUM BARBARUM EXTRACT; PROSTAGLANDIN E2; PLANT EXTRACT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG INHIBITION; ESTROGEN METABOLISM; HUMAN; HUMAN CELL; LYCIUM; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECT; FEMALE; METABOLISM; PATHOLOGY; PHYTOTHERAPY; TUMOR CELL LINE;

LYCIUM BARBARUM;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; FEMALE; HUMANS; LYCIUM; PHYTOTHERAPY; PLANT EXTRACTS; RECEPTORS, ESTROGEN;

EID: 67649396123     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802585952     Document Type: Article

References (39)

1. Jemal AR, Siegel R, Ward E, Murray T, Xu J, and Thun MJ: Cancer Statistics, 2007. CA Cancer J Clin 57, 43-66, 2007.
2. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3, 768-780, 2003.
3. Early Breast Cancer Trialists Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 years survival: an overview of the randomized trials. Lancet 365, 1687-1717, 2005.
4. Lippman ME: Efforts to combine endocrine and chemotherapy in the management of breast cancer: Do two and two equals three? Breast Cancer Res Treat 3, 117-127, 1983.
5. Tindle HA, Davis RB, Phillips RS, and Eisenberg DM: Trends in the use of complementary and alternative medicine by US adults: 1997-2002. Altern Ther Health Med 11, 42-49, 2005.
6. Molassiotis A, Scott JA, Kearny N, and Kearney N: Complementary and alternative medicine use in breast cancer patients in Europe. Support Care Cancer 14, 206-267, 2006.
7. Lu CX and Cheng BQ: Radiosensitizing effects of Lycium barbarum polysaccharides for Lewis lung cancer. Zhong. Xi. Yi. Jie. He. Za. Zhi. 11, 611, 1991. [PMID: 1806310, PubMed-Indexed for MEDLINE].
8. Cao GW, Yang WG, and Du P: Observations of the effects of LAK/IL- 2 therapy combining with Lycium barbarum polysaccharides in treatment of 75 cancer patients. Zhonghua. Zong. Liu. Za. Zhi. 16, 428-431, 1994. [PMID: 7720497, PubMed-Indexed for MEDLINE].
9. Zhang M, Chen H, Huang J, Li Z, Zhu C, and Zang S: Effect of Lycium barbarum polysaccharides on human hepatoma QGY 7703 cells: inhibition of proliferation and induction of apoptosis. Life Sci 18, 2115-2124, 2005.
10. Liu XL, Sun JY, Li HY, Zhang L, and Qian B: Extraction and isolation of active component for inhibiting PC-3 cell proliferation in vitro from the fruit of Lycium barbarum L. Zhongguo Zhong Yao Za Zhi 25, 481-483, 2000. [PMID: 12515210, PubMed-Indexed for MEDLINE].
11. Gau L,Hua, ZS, LIang, YX, and Bi XH: Immunomodualtion and anti-tumor activity by a polysaccharide-protein complex from Lycium barbarum. Int Immunopharmacol 4, 563-569, 2004.
12. Gong H, Shen P, Jin L, Xing C, and Tang F: Therapeutic effects of Lycium barbarum polysaccharide on irradiation or chemotherapy-induced myelosuppressive mice. Cancer Biother Radiopharm 20, 155-162, 2005.
13. Lippman ME,Osborne CK,Knazek R, andYoung N: In vitromodel systems for the study of hormone dependent human breast cancer. N Engl J Med 296, 154-159, 1977.
14. Suto A, Bradlow HL, Wong GY, Osborne MP, and Telang NT: Persistent estrogen responsiveness of ras oncogene transformed mouse mammary epithelial cells. Steroids 57, 262-268, 1992.
15. Fishman J, Osborne MP, and Telang NT: The role of estrogens in mammary carcinogenesis. Ann NY Acad Sci 768, 91-100, 1995.
16. Telang NT: Oncogenes, estradiol metabolism and mammary carcinogenesis. Ann NY Acad Sci 784, 277-287, 1996.
17. Suto A, Bradlow HL, Kubota T, Kitajima M, Wong GY, Osborne MP, and Telang NT: Alteration in proliferative and endocrine responsiveness of human mammary carcinoma cells by prototypic tumor suppressing agents. Steroids 58, 215-219, 1993.
18. Tiwari RK, Guo L, Bradlow HL, Telang NT, and Osborne MP: Selective responsiveness of human breast cancer cells to indole-3-carbinol, a chemopreventive agent. J Natl Cancer Inst 86, 126-131, 1994.
19. Telang NT, Katdare M, Bradlow HL, and Osborne MP: Cell cycle regulation, apoptosis and estradiol metabolism: novel end point biomarkers for human breast cancer prevention. J Clin Ligand Assay 23, 130-137, 2000.
20. Telang NT, Suto A,Wong GY, Osborne MP, and Bradlow HL: Induction by estrogen metabolite 16á-hydroxyestrone of gentoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84, 634-638, 1992.
21. Schneider J, Huh MM, Bradlow HL, and Fishman J: Antiestrogen action of 2-hydroxyestrone on MCF-7 human breast carcinoma cells. J Biol Chem 259, 4840-4845, 1984.
22. Lottering ML, Haag M, and Seegers JC: Effects of 17ß- estradiolmetabolites on cell cycle events in MCF-7 cells. Cancer Res 52, 5926-5932, 1992.
23. Castagnetta LM, Granata OM, Cocciadiferro L, et al.: Sex steroids, carcinogenesis and cancer progression. Ann NY Acad Sci 1028, 233-246, 2004.
24. Sepkovic DW,Bradlow HL,Michnovcz J,Murtezani S, Levy I, and Osborne MP: Catechol estrogen production in rat microsomes after treatment with Indole-3-Carbinol, Ascorbigen, or ß-napthaflavone: a comparison of stable isotope dilution gas chromatography-mass spectrometry and radiometric methods. Steroids 59, 318-323, 1994.
25. Dehennin L, Reiffsteck A, and Scholler R: Simple methods for the synthesis of twenty different highly enriched deuterium labeled steroids suitable as internal standards for isotope dilution mass spectrometry. Biochem Mass Spectrometry 7, 493-499, 1980.
26. Raju U, Sepkovic DW, Dixon, JM, Bradlow HL, and Levitz M: Estrone and estradiol metabolism in vivo in human breast cysts. Steroids 65, 883-888, 2000.
27. Jellnick PH, Makin HLJ, Sepkovic DW and Bradlow HL: Influence of indole carbinols and growth hormone on themetabolism of 4-androstenedione by rat liver mocrosomes. J Steroid Biochem Mol Biol 46, 791-798, 1993.
28. Fisher B, Constantino JP,Wickerman DL, Redmond CK, Kavanah M, et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90, 1371-1388, 1998.
29. Jordan VC: Historical perspective on hormonal therapy of advanced breast cancer. Clin Ther 24(ASuppl), A3-A16, 2002.
30. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 354, 270-282, 2006.
31. Kasid A, Lippman ME, Papageorge AG, Lowy Dw, and Gelman EP: Transfection of v-rasH DNA in to MCF-7 cells bypasses their dependence on estrogen for tumorigenecity. Science 228, 725-728, 1985.
32. Sommers CL, Papageorge AL, Wilding G, and Gelman EP: Growth properties and tumorigenesis of MCF-7 cells transfected with isogenic mutants of ras H. Cancer Res 50, 67-71, 1990.
33. Kurukava H, Lenferink AE, Simpson JE, Pisakane PI, Sliwkowski MX, et al.: Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER-2 overexpressing, tamoxifenresistant breast cancer cells. Cancer Res 60, 5887-5894, 2000.
34. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathi D, et al.: Esrtrogendependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24, 85-95, 1992.
35. Telang NT, Narayanan R, Bradlow HL, and Osborne MP: Co-ordinated expression of intermediate biomarkers for tumorigenic transformation of RAS-transfected mouse mammary epithelial cells. Breast Cancer Res Treat 18, 155-163, 1991.
36. Telang NT, Osborne MP, Sweterlisch L, and Narayanan R: Neoplastic transformation of mouse mammary epithelial cells by deregulated myc expression. Cell Reg 1, 863-872, 1990.
37. Schneider J, Kinne D, Frachhia A, Pierce V, Anderson KE, et al.: Abnormal oxidative metabolism of 17ß-estradiol in women with breast cancer. Proc Natl Acad Sci USA 79, 3047-3051, 1982.
38. Fishman J, Schneider J, Herschkopf RJ, and Bradlow HL: Increased estrogen 16á-hydroxylase activity inwomenwith breast and endometrial cancer. J Steroid Biochem Molec Biol 20, 1077-1081, 1984.
39. Suto A, Telang NT, Tanino H, Takeshita T, Ohmiya H, et al.: In vitro and in vivo modulation of growth regulation in the human breast cancer cell line MCF-7 by estradiol metabolites. Breast Cancer 6, 87-92, 1999.